Human Immunodeficiency Virus (HIV)

Select from the various topics below and click on the link to get an inside view of how our P&T committee responded to the issue. 

State Lotteries – Specialist describes state differences related to coverage of HIV agents

Multiple Guidelines – Specialist indicates that guidelines vary widely and indicate different preferred therapies.  There are more than one standard of care

Specialists Discuss Complexity of Patient Population – Specialists discuss impact of drug interactions, risk factors and pregnancy on therapy choice

Combination Drugs – Clinical Pharmacist discusses trade off between clinical and contracting with regard to combination therapies

Tolerability – Newer agents have improvement in tolerability

Formulary Considerations – Specialists discusses inability to narrow categories in HIV

Atripla as Preferred – Committee discusses preferring Atripla due to clinical merits

Genotyping – Committee discusses cost and benefits of genotyping

Contracting for Preferred – Discussion of designating either Rescriptor, Intelence or Viramune as preferred based on contracting

MC Push for Genotyping – PBM recommends pushing for genotyping before choice of therapy and PA of category

Trizivir and Combivir – Contracting pharmacist says combo more expensive than the three individual components

Impact of Combos on Adherence – Contracting pharmacist talks about savings of taking combos off formulary

Physician Competence – Specialist talks about the expertise of prescribers


* PTP video clips play in windows media player.  To download click here, Mac users click here. 
 
top of page